

# PROVIDERALERT



**To:** AmeriHealth Caritas Louisiana Providers

**Date:** April 28, 2025

**Subject:** LDH Approved Medical Drug Policies

**Summary:** LDH Approved Medical Drug Policies

AmeriHealth Caritas Louisiana would like to make you aware of two new policies that the Louisiana Department of Health has approved in accordance with La. R.S. 46:460.54. The guidelines will be located at the following link on our website under Pharmacy Prior Authorization Criteria:

<https://www.amerihealthcaritasla.com/pdf/pharmacy/acla-non-pdl-prior-auth-criteria.pdf>.

1. Pompe Disease Agents
2. Enzyme Replacement Therapy for Acid Sphingomyelinase Deficiency (ASMD)

Reminder: If your practice is not registered with our website portal, NaviNet, we highly recommend registering. To register, please visit [www.navinet.net](http://www.navinet.net) to sign up or contact your Provider Account Executive for details.

**Questions:**

Thank you for your continued support and commitment to our patients' care. If you have questions about this communication, please get in touch with AmeriHealth Caritas Louisiana's Provider Services department at 1-888-922-0007 or your [Provider Network Management Account Executive](#).

**Missed an alert?**

You can always find a complete list of provider alerts on our website's Newsletters and Updates page.

**Need to update your provider information?** Send full details to [network@amerihealthcaritasla.com](mailto:network@amerihealthcaritasla.com)



**PHARMACY  
PRIOR AUTHORIZATION  
CRITERIA**

Effective 05/10/2025

Field Name	Field Description
Prior Authorization Group Description	<b>Adzynma</b>
Drugs	Adzynma (ADAMTS13, recombinant-krhn)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See “other criteria”
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be a hematologist, oncologist, intensive care specialist, or specialist in the treatment of rare genetic hematologic diseases
Coverage Duration	<p><u>On-demand therapy:</u> If all criteria are met, the request will be approved for 1 month.</p> <p><u>Prophylactic therapy:</u> If all criteria are met, the initial request will be approved for 6 months. Reauthorization requests will be approved for 12 months.</p>
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b><u>Initial Authorization</u></b></p> <ul style="list-style-type: none"> <li>• Diagnosis of congenital thrombotic thrombocytopenic purpura (cTTP) as confirmed by BOTH of the following: <ul style="list-style-type: none"> <li>○ Molecular genetic testing</li> <li>○ ADAMTS13 activity &lt;10%</li> </ul> </li> <li>• Prescriber attestation that member has not been diagnosed with any other TTP-like disorder (i.e., microangiopathic hemolytic anemia, immune-mediated thrombotic thrombocytopenic purpura [iTTP])</li> <li>• If request is for prophylactic therapy, member must also have a history of at least one documented TTP event</li> <li>• Member’s weight</li> <li>• Request is for an FDA-approved dose</li> </ul> <p><b><u>Reauthorization</u></b></p> <ul style="list-style-type: none"> <li>• Documentation of positive clinical response to therapy (i.e., improvement in acute and subacute TTP events, platelet counts, microangiopathic hemolytic anemia episodes, or clinical symptoms)</li> <li>• Member’s weight</li> <li>• Request is for an FDA-approved dose</li> </ul>
Revision/Review Date:	4/2024

	<b>Medical Director/clinical reviewer may override criteria when, in his/her professional judgement, the requested item is medically necessary.</b>
--	---

Field Name	Field Description
Prior Authorization Group Description	<b>Alpha-1 Proteinase Inhibitors (Human)</b>
Drugs	<p><b><u>Preferred:</u></b> Prolastin-C</p> <p><b><u>Non-Preferred:</u></b> Aralast NP Glassia Zemaira Or any other newly marketed agent</p>
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	Members who have undergone liver transplantation
Required Medical Information	None
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or specialist in the treatment of AAT
Coverage Duration	The request will be approved for up to a 12 month duration
Other Criteria	<p><b>**Drug is being requested through the member's medical benefit**</b></p> <p><b>Initial Authorization:</b></p> <ul style="list-style-type: none"> <li>Documented diagnosis of a congenital deficiency of alpha-1 antitrypsin (AAT) (serum AAT level &lt; 11 micromol/L [approximately 57 mg/dL using nephelometry or 80mg/dl by radial immunodiffusion]).</li> <li>Documentation was submitted indicating the member has undergone genetic testing for AAT deficiency and is classified as phenotype PiZZ, PiSZ, PiZ(null) or Pi(null)(null) [NOTE: phenotypes PiMZ or PiMS are not candidates for treatment with Alpha1-Proteinase Inhibitors]</li> <li>Documentation was submitted (member's pulmonary function test results) indicating airflow obstruction by spirometry (forced expiratory volume in 1 second [FEV<sub>1</sub>] ≤ 65% of predicted), or provider has documented additional medical information demonstrating medical necessity</li> <li>Documentation was submitted indicating member is a non-smoker or an ex-smoker (eg. smoking cessation treatment)</li> <li>Documentation of the member's current weight</li> <li>The Alpha-1 Proteinase Inhibitor (human) is being prescribed at an FDA approved dosage</li> </ul>

<p>Revision/Review Date 2/2025</p>	<ul style="list-style-type: none"> <li>• If the medication request is for an Alpha1-Proteinase Inhibitor (human) product other than Prolastin-C, the patient has a documented medical reason (intolerance, hypersensitivity, contraindication, treatment failure, etc.) for not using Prolastin-C to treat their medical condition</li> </ul> <p><b>Reauthorization:</b></p> <ul style="list-style-type: none"> <li>• Documentation of the member's current weight</li> <li>• Documentation was submitted indicating member is a non-smoker or an ex-smoker (e.g. smoking cessation treatment)</li> <li>• Documentation was submitted indicating the member has clinically benefited from therapy (i.e. stable lung function, improved PFTs, alpha-1 antitrypsin serum level maintained above 11 micromol/L [approximately 57 mg/dL using or 80 mg/dL by radial immunodiffusion], improved quality of life)</li> <li>• The Alpha-1 Proteinase Inhibitor (human) is being prescribed at an FDA approved dosage</li> </ul> <p><b>Clinical reviewer/Medical Director must override criteria when, in his/her professional judgment, the requested item is medically necessary.</b></p>
--	---

Field Name	Field Description
Prior Authorization Group Description	<b>Amtagvi (lifileucel)</b>
Drugs	Amtagvi (lifileucel)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	<ul style="list-style-type: none"> <li>• Uncontrolled brain metastases</li> <li>• Melanoma of uveal or ocular origin</li> <li>• Systemic steroid therapy for any reason</li> </ul>
Required Medical Information	See “Other Criteria”
Age Restrictions	According to package insert
Prescriber Restrictions	Prescriber must be an oncologist
Coverage Duration	If all of the criteria are met, the initial request will be approved for a one-time treatment.
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Diagnosis of unresectable or metastatic melanoma (Stage IIIc or Stage IV)</li> <li>• Member must have progressed through at least one prior systemic therapy including a PD-1/PD-L1 blocking antibody and, if BRAF V600 mutation–positive, a BRAF inhibitor or BRAF inhibitor in combination with a MEK inhibitor</li> <li>• Member must have at least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm in diameter post-resection</li> <li>• Eastern Cooperative Oncology Group (ECOG) score of 0 or 1</li> <li>• Medication is prescribed at an FDA approved dose</li> </ul> <p><b>The safety and effectiveness of repeat administration of Amtagvi has not been evaluated and will not be approved.</b></p>
Revision/Review Date: 4/2024	<p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>

Field Name	Field Description
Prior Authorization Group Description	<b>Anti-CD19 CAR-T Immunotherapies</b>
Drugs	Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	Patients with primary central nervous system lymphoma
Required Medical Information	See “Other Criteria”
Age Restrictions	See “Other Criteria”
Prescriber Restrictions	Prescriber must be an oncologist, hematologist or other appropriate specialist
Coverage Duration	If all the criteria are met, the initial request will be approved for a one – time infusion per lifetime.
Other Criteria	<p><b><u>**Drug is being requested through the member’s medical benefit**</u></b></p> <p><b><u>Initial authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Patient must not have received prior anti-CD19 CAR-T therapy.</li> <li>• Patient will be screened for HBV, HCV, and HIV in accordance with clinical guidelines.</li> <li>• Patient does not have an active infection or inflammatory disorder.</li> <li>• Patient has a life expectancy &gt;12 weeks.</li> <li>• Patient will not receive live virus vaccines for at least 6 weeks prior to the start of lymphodepleting chemotherapy and until immune recovery following treatment.</li> <li>• Use is supported by a labeled indication or NCCN guidelines</li> </ul> <p><b><u>Leukemia</u></b></p> <p><b>B-cell precursor Acute Lymphoblastic Leukemia (ALL):</b></p> <ul style="list-style-type: none"> <li>• If the request is for Kymriah <ul style="list-style-type: none"> <li>○ Patient is 25 years of age or younger</li> <li>○ ALL that is refractory or in second or later relapse</li> </ul> </li> <li>• If the request is for Tecartus <ul style="list-style-type: none"> <li>○ Patient is 18 years of age or older</li> <li>○ ALL that is relapsed or refractory</li> </ul> </li> </ul>



**Chronic Lymphocytic Leukemia (CLL):**

- If the request is for Breyanzi
  - Patient is 18 years of age or older
  - Patient has relapsed/refractory disease defined as failure of two or more lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor AND a B-cell lymphoma 2 (BCL-2) inhibitor

**Non-Hodgkin's Lymphoma (NHL)****Follicular Lymphoma (FL):**

- If the request is for Breyanzi, Kymriah, or Yescarta:
  - Patient is 18 years of age or older
  - Patient has relapsed/refractory disease defined as failure of two or more lines of systemic therapy

**Large B-cell Lymphoma (LBCL), Diffuse Large B-cell Lymphoma (DLBCL) not otherwise specified, primary mediastinal high grade B-cell lymphoma, follicular lymphoma grade 3B, and DLBCL arising from follicular lymphoma:**

- If the request is for Breyanzi, Kymriah, or Yescarta
  - Patient is 18 years of age or older
  - For Breyanzi ONE of the following:
    - Patient is refractory to first-line chemoimmunotherapy or relapsed within 12 months of first-line chemoimmunotherapy
    - Patient is refractory to first-line chemoimmunotherapy or relapsed after first-line chemoimmunotherapy and is not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age
    - Patient has failed two or more lines of systemic therapy
  - For Kymriah: Patient has relapsed/refractory disease defined as failure of two or more lines of systemic therapy
  - For Yescarta ONE of the following:
    - Patient is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy or
    - Patient has failed two or more lines of systemic therapy

<p>Revision/Review Date: 7/2024</p>	<p><b>Mantle Cell Lymphoma (MCL):</b></p> <ul style="list-style-type: none"> <li>• If the request is for Tecartus: <ul style="list-style-type: none"> <li>○ Patient is 18 years of age or older</li> <li>○ Patient has relapsed/refractory disease defined as failure of BOTH the following lines of therapy: <ul style="list-style-type: none"> <li>▪ Chemoimmunotherapy such as an anti-CD20 monoclonal antibody (e.g. Rituxan) + any chemotherapeutic agent</li> <li>▪ Bruton Tyrosine Kinase (BTK) Inhibitor (e.g. Calquence, Imbruvica, Brukinsa)</li> </ul> </li> </ul> </li> </ul> <p><b>Small Lymphocytic Lymphoma (SLL):</b></p> <ul style="list-style-type: none"> <li>• If the request is for Breyanzi <ul style="list-style-type: none"> <li>○ Patient is 18 years of age or older</li> <li>○ Patient has received at least 2 prior lines of therapy including, a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor</li> </ul> </li> </ul> <p><b><u>Re-authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Treatment exceeding 1 dose per lifetime will not be authorized.</li> </ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>
---	--

Prior Authorization Group Description	<b>Anti-FGF23 Monoclonal Antibodies</b>
Drugs	Crysvita (burosumab) SQ solution, or any other newly marketed agent
Covered Uses	Medically accepted indications are defined using the following sources: The Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	See Other Criteria
Required Medical Information	See Other Criteria
Age Restrictions	X-linked hypophosphatemia (XLH): 6 months of age or older Tumor-induced osteomalacia (TIO): 2 years of age and older
Prescriber Restrictions	Prescribed by, or in consultation with, an endocrinologist, nephrologist, molecular geneticist, or other specialist experienced in the treatment of metabolic bone disorders
Coverage Duration	If all of the criteria are met, the initial request will be approved for 6 months and reauthorization requests will be approved for 12 months. If the conditions are not met, the request will be sent to a Medical Director/clinical reviewer for medical necessity review
Other Criteria	<p><b><u>**Drug is being requested through the member's medical benefit**</u></b></p> <p><b><u>Initial Authorization:</u></b></p> <p><b>For X-linked hypophosphatemia (XLH):</b></p> <ul style="list-style-type: none"> <li>• Diagnosis of XLH</li> <li>• Dosing is appropriate as per labeling or is supported by compendia or standard of care guidelines</li> <li>• Labs, as follows: <ul style="list-style-type: none"> <li>○ Serum phosphorus below normal for patient age</li> <li>○ eGFR &gt; 30 mL/min/1.73 m<sup>2</sup> or CrCl ≥ 30 mL/min</li> </ul> </li> <li>• Patient will not use concurrent oral phosphate and/or active vitamin D analogs (e.g. calcitriol, paricalcitol, doxercalciferol, calcifediol)</li> <li>• Additionally, for adults: <ul style="list-style-type: none"> <li>○ Clinical signs and symptoms of XLH (e.g. bone/joint pain, fractures, osteomalacia, osteoarthritis, enthesopathies, spinal stenosis impaired mobility, presence or history of lower limb deformities, etc.)</li> <li>○ Trial and failure of, or contraindication to, combination therapy with oral phosphate and active vitamin D (calcitriol) for a minimum of 8 weeks</li> </ul> </li> </ul>

<p>Revision/Review Date: 7/2024</p>	<p><b>For tumor-induced osteomalacia (TIO):</b></p> <ul style="list-style-type: none"> <li>• Diagnosis of FGF23-related hypophosphatemia in TIO</li> <li>• Dosing is appropriate as per labeling or is supported by compendia or standard of care guidelines</li> <li>• The tumor(s) is/are not amenable to surgical excision or cannot be located</li> <li>• Labs, as follows: <ul style="list-style-type: none"> <li>○ Serum phosphorus below normal for patient age</li> <li>○ eGFR &gt; 30 mL/min/1.73 m<sup>2</sup> or CrCl ≥ 30 mL/min</li> </ul> </li> <li>• Patient will not use concurrent oral phosphate and/or active vitamin D analogs (e.g. calcitriol, paricalcitol, doxercalciferol, calcifediol)</li> </ul> <p><b><u>Re-authorization:</u></b></p> <p><b>For XLH or TIO:</b></p> <ul style="list-style-type: none"> <li>• Documented effectiveness as evidenced by at least one of the following: <ul style="list-style-type: none"> <li>○ Serum phosphorus within normal limits for patient age</li> <li>○ Clinical improvement (e.g. improved rickets, improved bone histomorphometry, increased growth velocity, increased mobility, decrease in bone fractures, improved fracture healing, reduction in bone-related pain)</li> </ul> </li> <li>• 25-hydroxyvitamin D level and, if abnormally low, documented supplementation with cholecalciferol or ergocalciferol</li> <li>• Patient is not concurrently using oral phosphate and/or active vitamin D analogs (e.g. calcitriol, paricalcitol, doxercalciferol, calcifediol)</li> <li>• Dosing continues to be appropriate as per labeling or is supported by compendia or standard of care guidelines</li> </ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>
---	--

Field Name	Field Description
Prior Authorization Group Description	<b>B-Cell Maturation Antigen (BCMA) Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy</b>
Drugs	Abecma (idecabtagene vicleucel) , Carvykti (ciltacabtagene autoleucel)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), and the Drug Package Insert (PPI).
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restrictions	Member must be 18 years or older
Prescriber Restrictions	Prescriber must be a hematologist, an oncologist, or other appropriate specialist
Coverage Duration	If all the criteria are met, the initial request will be approved for a one – time infusion per lifetime.
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b><u>Initial Authorization</u></b></p> <ul style="list-style-type: none"> <li>• Member has a diagnosis of relapsed or refractory multiple myeloma (RRMM)</li> <li>• For Abecma, member must also have received at least 2 prior lines of therapy including: <ul style="list-style-type: none"> <li>○ An immunomodulatory agent (e.g. lenalidomide, pomalidomide, thalidomide)</li> <li>○ A proteasome inhibitor (e.g. bortezomib, carfilzomib, ixazomib)</li> <li>○ An anti-CD38 monoclonal antibody (e.g. daratumumab, isatuximab)</li> </ul> </li> <li>• For Carvykti, member must also be refractory to lenalidomide AND have received at least 1 prior line of therapy including: <ul style="list-style-type: none"> <li>○ An immunomodulatory agent (e.g. lenalidomide, pomalidomide, thalidomide)</li> <li>○ A proteasome inhibitor (e.g. bortezomib, carfilzomib, ixazomib)</li> </ul> </li> <li>• Member does not have an active infection</li> <li>• Member will be screened for cytomegalovirus (CMV), hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) in accordance with clinical guidelines</li> <li>• Member will not receive live virus vaccines for at least 6 weeks prior to the start of lymphodepleting chemotherapy and until immune recovery following treatment</li> <li>• Member has not previously received a BCMA CAR-T therapy</li> </ul> <p><b><u>Re-authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Treatment exceeding 1 dose per lifetime will not be authorized.</li> </ul>
Revision/Review Date 7/2024	

	<b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b>
--	--

.

Field Name	Field Description
Prior Authorization Group Description	<b>Blincyto</b>
Drugs	Blincyto (blinatumomab)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restriction	N/A
Prescriber Restrictions	Prescriber must be an oncologist/hematologist
Coverage Duration	The request will be approved for up to a 12 month duration
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b>Initial Authorization:</b></p> <ul style="list-style-type: none"> <li>• Patient has a diagnosis of one of the following forms of Acute Lymphoblastic Leukemia (ALL): <ul style="list-style-type: none"> <li>a) Relapsed CD19-positive B-cell precursor ALL</li> <li>b) Refractory CD19-positive B-cell precursor ALL</li> <li>c) B-cell precursor CD-positive ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%</li> </ul> </li> <li>• Provider attests to monitor patient for Cytokine Release Syndrome (CRS) and neurological toxicities</li> </ul> <p><b>Reauthorization:</b></p> <ul style="list-style-type: none"> <li>• Patient has a diagnosis of relapsed or refractory CD19-positive B-cell precursor ALL and has not exceeded 9 total cycles of Blincyto therapy</li> <li>• Provider attests to treatment response or stabilization of disease</li> <li>• Prescriber attests to monitor patient for Cytokine Release Syndrome (CRS) and neurological toxicities</li> </ul>
Revision/Review Date 4/2024	<p>***For CD19-positive B-cell precursor ALL with MRD, reauthorization is not allowed***</p> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>

Field Name	Field Description
Prior Authorization Group Description	<b>Brineura (cerliponase alfa)</b>
Drugs	Brineura (cerliponase alfa)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), and the Drug Package Insert, and/or per the National Comprehensive Cancer Network (NCCN)
Exclusion Criteria	N/A
Required Medical Information	See “other criteria”
Age Restrictions	Member must be 3 years of age or older
Prescriber Restrictions	Prescriber must be a neurologist
Coverage Duration	If the criteria are met, the request will be approved for 12 months.
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Documentation of confirmed diagnosis of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) with one of the following: <ul style="list-style-type: none"> <li>○ Lab results demonstrating deficient TPP1 enzyme activity</li> <li>○ Identification of causative mutations in the TPP1/CLN2 gene</li> </ul> </li> <li>• Documentation of baseline CLN2 Clinical Rating Scale motor +language score. Baseline CLN2 score must be &gt; 0.</li> <li>• Medication is prescribed at an FDA approved dose</li> </ul> <p><b><u>Re-authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Documentation of CLN2 Clinical Rating Scale motor +language score has remained &gt; 0</li> <li>• Medication is prescribed at an FDA approved dose</li> </ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgment, the requested item is medically necessary.</b></p>
Revision/Review Date: 7/2024	



Field Name	Field Description
Prior Authorization Group Description	<b>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Agents</b>
Drugs	Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See "Other Criteria"
Age Restrictions	Per FDA-approved labeling
Prescriber Restrictions	Prescriber must be a neurologist or neuromuscular specialist.
Coverage Duration	If all of the criteria are met, the initial request will be approved for 3 months. For continuation of therapy, the request will be approved for 12 months.
Other Criteria	<p><b>**Drug is being requested through the member's medical benefit**</b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Diagnosis of CIDP confirmed by electrodiagnostic test results (e.g. electromyography or nerve conduction studies)</li> <li>• Patient has progressive or relapsing/remitting disease course for <math>\geq 2</math> months</li> <li>• Patient has an inadequate response, significant intolerance, or contraindication to intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG)</li> <li>• Medication is prescribed at an FDA approved dose</li> </ul> <p><b><u>Re-Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Documentation or provider attestation of significant clinical improvement in neurologic symptoms or stabilization of disease</li> <li>• Medication is prescribed at an FDA approved dose</li> </ul> <p><b>If all of the above criteria are not met, the request is referred to a Medical Director/Clinical Reviewer for medical necessity review.</b></p>

Date: 11/2024

Field Name	Field Description
Prior Authorization Group Description	<b>Complement Inhibitors</b>
Drugs	<b>Soliris (eculizumab), Ultomiris (ravulizumab), Empaveli (pegcetacoplan), Syfovre (pegcetacoplan injection), Fabhalta (iptacopan), Voydeya (danicopan), Izervay (avacincaptad pegol injection), PiaSky (crovalimab-akkz)</b>
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, the Drug Package Insert, and/or per the standard of care guidelines
Exclusion Criteria	N/A
Required Medical Information	See “other criteria”
Age Restrictions	According to package insert
Prescriber Restrictions	Prescriber must be a hematologist, nephrologist, neurologist, oncologist, ophthalmologist, or other appropriate specialist.
Coverage Duration	<p>If the criteria are met, criteria will be approved as follows:</p> <p>Initial Requests</p> <ul style="list-style-type: none"> <li>• 3 months: Soliris (eculizumab), Ultomiris (ravulizumab), Empaveli (pegcetacoplan), Voydeya (danicopan)</li> <li>• 6 months: Fabhalta (iptacopan), PiaSky (crovalimab-akkz)</li> <li>• 12 months: Syfovre (pegcetacoplan), Izervay (avacincaptad pegol)</li> </ul> <p>Reauthorization</p> <ul style="list-style-type: none"> <li>• 6 months: Soliris (eculizumab), Ultomiris (ravulizumab), Empaveli (pegcetacoplan), Voydeya (danicopan)</li> <li>• 12 months: Syfovre (pegcetacoplan), Fabhalta (iptacopan), PiaSky (crovalimab-akkz)</li> </ul> <p>No Reauthorization</p> <ul style="list-style-type: none"> <li>• Izervay (avacincaptad pegol)</li> </ul>
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• The request is for a dose that is FDA approved or in nationally recognized compendia in accordance with the patient’s diagnosis, age, body weight, and concomitant medical conditions; <b>AND</b></li> <li>• For Fabhalta (iptacopan), Soliris (eculizumab), Ultomiris (ravulizumab), Empaveli (pegcetacoplan), PiaSky (crovalimab-akkz), and Voydeya (danicopan) <ul style="list-style-type: none"> <li>○ Documentation patient complies with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria.</li> </ul> </li> </ul>

**Paroxysmal Nocturnal Hemoglobinuria (PNH):**

- Documentation of diagnosis by high sensitivity flow cytometry
- Hemoglobin (Hgb) < 10.5 g/dL for Empaveli (pegcetacoplan), or HgB < 10 g/dL for Fabhalta (iptacopan)
- For Voydeya (danicopan):
  - Member has been receiving Soliris (eculizumab) or Ultomiris (ravulizumab) therapy for at least 6 months
  - Member has clinically evident extravascular hemolysis [defined as anemia (Hgb  $\leq$  9.5 gram/deciliter) with absolute reticulocyte count  $\geq 120 \times 10^9$ /liter] despite treatment with Soliris (eculizumab) or Ultomiris (ravulizumab)
  - Voydeya (danicopan) will be used as add-on therapy to Soliris (eculizumab) or Ultomiris (ravulizumab)

**Generalized Myasthenia Gravis (gMG):**

- The request is for Soliris (eculizumab) or Ultomiris (ravulizumab)
- Patient has a positive serologic test for anti-AChR antibodies; **AND**
- Patient has a Myasthenia Gravis Foundation of America (MGFA) clinical classification of class II, III or IV at initiation of therapy; **AND**
- Patient has a Myasthenia Gravis-specific Activities of Daily Living scale (MG-ADL) total score  $\geq 6$  at initiation of therapy; **AND**
- One of the following:
  - Failed treatment over a total of 1 year or more with 2 or more immunosuppressive therapies (ISTs) either in combination or as monotherapy; **OR**
  - Failed at least 1 IST and required chronic plasmapheresis or plasma exchange or intravenous immunoglobulin; **OR**
  - Has a documented history of contraindications or intolerance to ISTs

**Neuromyelitis Optica Spectrum Disorder (NMOSD)**

- Refer to the “Neuromyelitis Optica Spectrum Disorder (NMOSD) Agents” policy

**Atypical Hemolytic Uremic Syndrome (aHUS)/Complement-Mediated HUS)**

- Documentation of confirmed diagnosis as evidenced by complement genotyping and complement antibodies; **OR**

Revision/Review  
Date 11/2024

- Provider attestation treatment is being used empirically and delay in therapy will lead to unacceptable risk to the patient

**Geographic Atrophy (GA):**

- If the request is for Syfovre (pegcetacoplan injection), member must be  $\geq 60$  years of age
- If the request is for Izervay (avacincaptad pegol injection), member must be  $\geq 50$  years of age
- Diagnosis of GA secondary to age-related macular degeneration (AMD)
- Absence of choroidal neovascularization (CNV) in treated eye
- Best-corrected visual acuity (BCVA)  $\geq 24$  letters Early Treatment Diabetic Retinopathy Study (ETDRS)
- GA lesion size  $> 2.5$  and  $< 17.5$  mm<sup>2</sup> with at least 1 lesion  $> 1.25$  mm<sup>2</sup>

**Re-Authorization:**

- Re-authorization may be considered for all agents included in these criteria with the exception of Izervay (avacincaptad pegol injection), which is only indicated for a 12 month duration
- Provider has submitted documentation of clinical response to therapy (e.g., reduction in disease severity, improvement in quality of life scores, increase in Hgb, reduced need for blood transfusions, slowing of growth rate of GA lesions, etc.); **AND**
- The request is for a dose that is FDA approved or in nationally recognized compendia in accordance with the patient's diagnosis, age, body weight, and concomitant medical condition; **AND**
- If the request is for aHUS/Complement Mediated HUS
  - Documentation of confirmed diagnosis as evidenced by complement genotyping and complement antibodies

**Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.**

Field Name	Field Description
Prior Authorization Group Description	<b>Dendritic Cell Tumor Peptide Immunotherapy</b>
Drugs	Provenge (sipuleucel-T)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	Small cell/neuroendocrine prostate cancer
Required Medical Information	See “Other Criteria”
Age Restrictions	See “Other Criteria”
Prescriber Restrictions	Prescriber must be an oncologist or urologist
Coverage Duration	3 doses per lifetime
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>Metastatic castrate resistant (hormone-refractory) prostate cancer (mCRPC) (consistent with medical chart history) <ul style="list-style-type: none"> <li>Evidenced by soft tissue and/or bony metastases</li> <li>Patient does NOT have <ul style="list-style-type: none"> <li>M0CRPC (defined as CRPC whose only evidence of disseminated disease is an elevated serum PSA) is not authorized</li> <li>Visceral metastases (e.g. liver, lung, adrenal, peritoneal, brain)</li> </ul> </li> </ul> </li> <li>Patient is not currently being treated with systemic immunosuppressants (e.g. chemotherapy, corticosteroids) or, if the patient is being treated with immunosuppressants, the prescriber has provided a valid medical reason for combination therapy</li> <li>Eastern Cooperative Oncology Group (ECOG) score 0-1</li> <li>Serum testosterone &lt;50 ng/dL (e.g. castration levels of testosterone)</li> <li>Predicted survival of at least six months</li> </ul> <p><b><u>Reauthorization:</u></b></p> <ul style="list-style-type: none"> <li>Treatment exceeding 3 doses per lifetime will not be authorized</li> </ul>
Revision/Review Date 4/2024	

	<b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b>
--	--

Field Name	Field Description
Prior Authorization Group Description	<b>Enzyme Replacement Therapy for Acid Sphingomyelinase Deficiency (ASMD)</b>
Drugs	Xenpozyme (olipudase alfa-rpcp)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See "Other Criteria"
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, a specialist experienced in the treatment of ASMD
Coverage Duration	If all the criteria are met, the initial request will be approved for 6 months. For continuation of therapy, the request will be approved for 12 months.
Other Criteria	<p><b><u>**Drug is being requested through the member's medical benefit**</u></b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>Medication is prescribed at an FDA approved dose</li> <li>Member has a diagnosis of ASMD confirmed by one of the following: <ul style="list-style-type: none"> <li>Deficiency in acid sphingomyelinase (ASM) enzyme activity (as measured by peripheral blood leukocytes, cultured skin fibroblasts, or dried blood spots)</li> <li>Sphingomyelin phosphodiesterase-1 (SMPD1) gene mutation</li> </ul> </li> <li>Member has a clinical presentation consistent with ASMD type B or type A/B</li> <li>Documentation of members height and weight</li> <li>Documentation of baseline ALT and AST within 1 month prior to initiation of treatment</li> </ul> <p><b><u>Re-Authorization:</u></b></p> <ul style="list-style-type: none"> <li>Documentation or provider attestation of positive clinical response (i.e. improvement in splenomegaly, hepatomegaly, pulmonary function, etc.)</li> <li>Medication is prescribed at an FDA approved dose</li> </ul> <p><b>If all of the above criteria are not met, the request is referred to a Medical Director/Clinical Reviewer for medical necessity review.</b></p>

Date: 2/2025

Field Name	Field Description
Prior Authorization Group Description	Emergency Use Authorization (EUA) Drugs/Products for COVID-19
Drugs	Any drug/product authorized by EUA for COVID-19
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Emergency Use Authorization for the drug/product in question, and the Drug Package Insert (PPI).
Exclusion Criteria	See “Other Criteria”
Required Medical Information	See “Other Criteria”
Age Restrictions	As outlined within current FDA Emergency Use Authorization (EUA) guidelines
Prescriber Restrictions	N/A
Coverage Duration	As outlined within current FDA Emergency Use Authorization (EUA) guidelines
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p>Emergency Use Authorization for COVID-19 related drugs/products (all must apply):</p> <ul style="list-style-type: none"> <li>• The requested drug/product has a currently active Emergency Use Authorization as issued by the U.S. Food and Drug Administration.</li> <li>• Use of the requested drug/product is consistent with the current terms and conditions of the emergency use authorization (such as appropriate age/weight, formulation, disease severity, concurrent use with other medications or medical interventions, etc.).</li> <li>• By submitting an authorization request the prescriber attests they are not requesting reimbursement for ingredient cost of the drug when it is provided by U.S. government at no change.</li> </ul>
Revision/Review Date 2/2025	<p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>



Field Name	Field Description
Prior Authorization Group Description	<b>Enzyme Replacement Therapies for Fabry Disease</b>
Drugs	Fabrazyme (agalsidase beta) Elfabrio (peguniigalsidase alfa)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), and the Drug Package Insert (PPI).
Exclusion Criteria	N/A
Required Medical Information	See “other criteria”
Age Restrictions	According to the FDA approved prescribing information
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, cardiologist, nephrologist or specialist experienced in the treatment of Fabry disease
Coverage Duration	Initial Authorization: If the criteria are met, the request will be approved for a 6-month duration. Reauthorization: If the criteria are met, the request will be approved for a 12-month duration.
Other Criteria	<p><b><u>**Drug is being requested through the member’s medical benefit**</u></b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>Male members must have a documented diagnosis of Fabry disease confirmed by <u>one</u> of the following: <ol style="list-style-type: none"> <li>An undetectable (&lt;1%) alpha galactosidase A (alpha-Gal-A) activity level OR</li> <li>A deficient alpha-Gal- activity level AND a documented detection of pathogenic mutations in the galactosidase alpha (<i>GLA</i>) gene by molecular genetic testing</li> </ol> </li> <li>Female members must have a documented diagnosis of Fabry disease confirmed by detection of pathogenic mutations in the <i>GLA</i> gene by molecular genetic testing AND evidence of clinical manifestation of the disease (e.g. kidney, neurologic, cardiovascular, gastrointestinal)</li> <li>Member must not be using concurrently with Galafold (migalastat)</li> <li>Documentation of the member’s current weight</li> <li>Request is for an FDA-approved dose</li> </ul> <p><b><u>Re-Authorization:</u></b></p>

<p>Revision/Review Date: 7/2024</p>	<ul style="list-style-type: none"> <li>• Documentation that member has experienced an improvement in symptoms from baseline including but not limited to: decreased pain, decreased gastrointestinal manifestations, decrease in proteinuria, stabilization of increase in eGFR, reduction of left ventricular hypertrophy (LVH) on echocardiogram, or improved myocardial function, or has remained asymptomatic</li> <li>• Member must not be using concurrently with Galafold (migalastat)</li> <li>• Documentation of the member's current weight</li> <li>• Request is for an FDA-approved dose</li> </ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>
---	---

Field Name	Field Description
Prior Authorization Group Description	<b>Hydroxyprogesterone caproate (generic Delalutin)</b>
Drugs	Hydroxyprogesterone caproate (generic Delalutin)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	Pregnancy
Required Medical Information	See "Other Criteria"
Age Restrictions	According to package insert
Prescriber Restrictions	Prescriber must be a gynecologist or in consultation with a gynecologist
Coverage Duration	If all the criteria are met, the initial request will be approved for up to 6 months. For continuation of therapy, the request will be approved for up to 6 months.
Other Criteria	<p><b>**Drug is being requested through the member's medical benefit**</b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Medication is prescribed at an FDA approved dose</li> <li>• If request is for preterm birth, do not approve</li> <li>• Request is for one of the following indications: <ul style="list-style-type: none"> <li>○ Amenorrhea or abnormal uterine bleeding due to hormonal imbalance</li> <li>○ Production of secretory endometrium and desquamation</li> <li>○ Test for endogenous estrogen production</li> <li>○ Advanced uterine adenocarcinoma</li> </ul> </li> </ul> <p><b><u>Re-Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Documentation or provider attestation of clinical benefit</li> <li>• Medication is prescribed at an FDA approved dose</li> </ul> <p><b>If all the above criteria are not met, the request is referred to a Medical Director/Clinical Reviewer for medical necessity review.</b></p>
Revision/Review Date: 4/2024	

Field Name	Field Description
Prior Authorization Group Description	<b>Insulin-Like Growth Factor-1 Receptor (Igf-1r) Antagonists For Thyroid Eye Disease</b>
Drugs	Tepezza (teprotumumab-trbw)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restrictions	Member must be 18 years age or older
Prescriber Restrictions	Prescriber must be an ophthalmologist, endocrinologist, or specialist with expertise in the treatment of Grave’s disease with thyroid eye disease.
Coverage Duration	If all of the criteria are met, the request will be approved for up to 24 weeks of treatment (8 total infusions). Retreatment requests will not be allowed beyond the 8 dose limit.
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b><u>Initial Authorization:</u></b></p> <p>Tepezza is approved when all of the following are met:</p> <ul style="list-style-type: none"> <li>• Dosing does not exceed dosing guidelines as outlined in the package insert</li> <li>• Patient has a confirmed diagnosis of Graves’ disease</li> <li>• Documentation of moderate-severe thyroid eye disease as evidenced by one or more of the following: <ul style="list-style-type: none"> <li>○ Lid retraction of &gt;2mm</li> <li>○ Moderate or severe soft-tissue involvement</li> <li>○ Proptosis <math>\geq</math>3mm above normal values for race and sex</li> <li>○ Periodic or constant diplopia</li> </ul> </li> <li>• Patient must be euthyroid or thyroxine and free triiodothyronine levels are less than 50% above or below normal limits (submit laboratory results with request)</li> <li>• Patients of reproductive potential: attestation the patient is not pregnant, and appropriate contraception methods will be used before, during, and 6 months after the last infusion</li> </ul>

<p>Revision/Review Date 7/2024</p>	<ul style="list-style-type: none"> <li>• Patient has had a trial and therapy failure of, or contraindication to: <ul style="list-style-type: none"> <li>○ For active disease: oral or IV glucocorticoids</li> <li>○ For chronic/inactive disease: rehabilitative surgery</li> </ul> </li> </ul> <p><b><u>Re-authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Retreatment or renewal requests beyond a total of 24 weeks of treatment (8 total infusions) will not be allowed.</li> </ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>
--	---

Field Name	Field Description
Prior Authorization Group Description	<b>Ketamine</b>
Drugs	Ketamine (Ketalar)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restrictions	N/A
Prescriber Restrictions	Depression: N/A Complex Regional Pain Syndrome (CRPS): pain management specialist
Coverage Duration	Initial: 4 weeks Continuation of therapy: 6 months
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b><u>Depression</u></b></p> <p><b>Initial Authorization:</b></p> <ul style="list-style-type: none"> <li>• Diagnosis of major depressive disorder (MDD) or treatment-resistant depression (TRD)</li> <li>• Documented trial and failure of two preferred oral antidepressants (e.g. SSRIs, SNRIs, TCAs) of at least a minimum effective dose for four (4) weeks or longer OR a medical justification as to why the patient cannot use preferred alternative(s).</li> </ul> <p><b>Re-authorization:</b></p> <ul style="list-style-type: none"> <li>• Documentation was submitted indicating the member has clinically benefited from therapy.</li> </ul> <p><b><u>CRPS</u></b></p> <p><b>Initial Authorization:</b></p> <ul style="list-style-type: none"> <li>• Diagnosis of CRPS (may also be termed reflex sympathetic dystrophy, algodystrophy, causalgia, Sudeck atrophy, transient osteoporosis, and acute atrophy of bone)</li> <li>• Patient has tried and failed at least 8 weeks treatment with or</li> </ul>

<p>Revision/Review Date 4/2024</p>	<p>continues to receive physical therapy (PT) and/or occupational therapy (OT).</p> <ul style="list-style-type: none"> <li>• Patient has tried and failed at least two of the following: <ul style="list-style-type: none"> <li>○ NSAIDs</li> <li>○ Anticonvulsants (e.g. gabapentin, pregabalin)</li> <li>○ Antidepressants (e.g. SNRIs, TCAs)</li> <li>○ Bisphosphonate (in the setting of abnormal uptake on bone scan)</li> </ul> </li> </ul> <p><b>Re-authorization:</b></p> <ul style="list-style-type: none"> <li>• Patient has demonstrated clinical benefit.</li> </ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>
--	--

Field Name	Field Description
Prior Authorization Group Description	<b>Lamzede</b>
Drugs	Lamzede (velmanase alfa-tycv)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	“See Other Criteria”
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a specialist in the treatment of alpha-mannosidosis or other lysosomal storage disorders
Coverage Duration	If all of the criteria are met, the request will be approved for 12 months
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b>Initial Authorization</b></p> <ul style="list-style-type: none"> <li>• Diagnosis of alpha-mannosidosis as confirmed by one of the following: <ul style="list-style-type: none"> <li>○ Deficiency in alpha-mannosidase enzyme levels or activity in blood leukocytes</li> <li>○ DNA testing</li> </ul> </li> <li>• Prescriber attests that medication will only be used to treat non-central nervous system manifestations of alpha-mannosidosis</li> <li>• Patient’s weight</li> <li>• Dosing is consistent with FDA-approved labeling or is supported by compendia or standard of care guidelines</li> </ul> <p><b>Reauthorization</b></p> <ul style="list-style-type: none"> <li>• Patient has demonstrated a clinical response (i.e., reduction in serum oligosaccharide concentrations, stabilization or improvement in 3-minute stair climbing test [3MSCT], 6-minute walking test [6-MWT], forced vital capacity [FVC], etc.)</li> <li>• Prescriber attests that medication will only be used to treat non- central nervous system manifestations of alpha-mannosidosis</li> <li>• Patient’s weight</li> <li>• Dosing is consistent with FDA-approved labeling or is supported by compendia or standard of care guidelines</li> </ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>
Revision/Review Date 4/2024	



Field Name	Field Description
Prior Authorization Group Description	<b>Myasthenia Gravis Agents</b>
Drugs	Rystiggo (rozanolixizumab), Soliris (eculizumab), Ultomiris (ravulizumab), Vyvgart (efgartigimod), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase), Zilbrysq (zilucoplan)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See "Other Criteria"
Age Restrictions	≥ 18 years
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or rheumatologist
Coverage Duration	If all of the criteria are met, the initial request will be approved for 6 months. For continuation of therapy, the request will be approved for 12 months.
Other Criteria	<p><b>**Drug is being requested through the member's medical benefit**</b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Diagnosis of generalized myasthenia gravis (gMG)</li> <li>• Patient has a positive serological test for one of the following: <ul style="list-style-type: none"> <li>○ Anti-AChR antibodies</li> <li>○ Anti-muscle-specific tyrosine kinase (MuSK) antibodies (Rystiggo only)</li> </ul> </li> <li>• Patient has a Myasthenia Gravis Foundation of America (MGFA) clinical classification of class II, III or IV</li> <li>• Patient has tried and failed, or has contraindication, to one of the following: <ul style="list-style-type: none"> <li>○ Two (2) or more conventional therapies (i.e. acetylcholinesterase inhibitors, corticosteroids, non-steroidal immunosuppressive therapies)</li> <li>○ Failed at least 1 conventional therapy and required chronic plasmapheresis or plasma exchange or intravenous immunoglobulin</li> </ul> </li> <li>• Medication is prescribed at an FDA approved dose</li> <li>• Patient is not using agents covered by this policy concurrently (i.e. no concurrent use of Vyvgart, Vyvgart Hytrulo, Rystiggo, Soliris, Ultomiris, or Zilbrysq)</li> <li>• For Vyvgart Hytrulo, patient has tried and failed, or has</li> </ul>

<p>Revision/Review Date: 4/2024</p>	<p>contraindication, to Vyvgart</p> <ul style="list-style-type: none"> <li>• Requests for Soliris (eculizumab) Ultomiris (ravulizumab), and Zilbrysq (zilucoplan) will also require all of the following: <ul style="list-style-type: none"> <li>○ Patient has tried and failed, or has contraindication, to Vyvgart, Vyvgart Hytrulo, or Rystiggo.</li> <li>○ Documentation patient complies with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal infections in patients receiving a complement inhibitor.</li> </ul> </li> </ul> <p><b><u>Re-Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Provider has submitted documentation of clinical response to therapy (e.g., reduction in disease severity, improvement in quality-of-life scores, MG-ADL scores, etc).</li> <li>• Medication is prescribed at an FDA approved dose.</li> </ul> <p><b>If all of the above criteria are not met, the request is referred to a Medical Director/Clinical Reviewer for medical necessity review.</b></p>
---	---

Field Name	Field Description
Prior Authorization Group Description	<b>Omisirge</b>
Drugs	<b>Omisirge (omidubicel-only)</b>
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	Patient has previously received this medication
Required Medical Information	See "Other Criteria"
Age Restrictions	According to package insert
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	If all the criteria are met, the initial request will be approved for a one-time treatment.
Other Criteria	<p><b>**Drug is being requested through the member's medical benefit**</b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Patient has a hematologic malignancy planned for umbilical cord blood transplantation (UCBT) following myeloablative conditioning</li> <li>• Prescriber attests that the patient is eligible for myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) AND does not have a readily available matched related donor, matched unrelated donor, mismatched unrelated donor, or haploidentical donor</li> <li>• Patient has not received a prior allogenic HSCT</li> <li>• Patient does not have known allergy to dimethyl sulfoxide (DMSO), Dextran 40, gentamicin, human serum albumin, or bovine material</li> </ul> <p><b>The safety and effectiveness of repeat administration of Omisirge have not been evaluated and will not be approved.</b></p> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>
Review/Revision Date: 7/2024	

Field Name	Field Description
Prior Authorization Group	<b>Oncology Drugs/Therapies</b>
Drugs	Oral and Injectable Oncology Medications and Oncology Gene Therapies (specialty or non-specialty) without product specific criteria when requested for an oncology diagnosis
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI) , and the Drug Package Insert, and/or per the National Comprehensive Cancer Network (NCCN)
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restrictions	N/A
Prescriber Restrictions	Prescriber is an oncologist, or specialist in type of cancer being treated
Coverage Duration	If the criteria are met, the request will be approved for up to 6 month duration; if the criteria are not met, the request will be referred to a clinical reviewer for medical necessity review.
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b>All of the following criteria must be met:</b></p> <ul style="list-style-type: none"> <li>• Requested use must be a labeled indication or be supported by NCCN Category 1 or 2A level of evidence. If the request is for an off-label use supported by NCCN as Category 2B recommendation then medical documentation has been provided as to why member is unable to utilize a treatment regimen with a higher level of evidence (e.g. allergic reaction, contraindication)</li> <li>• Documentation has been provided of the results of all required genetic testing where required per drug package insert</li> <li>• Documentation has been provided of the results of all required laboratory values and patient specific information (e.g. weight, ALT/AST, Creatine Kinase, etc.) necessary to ensure the patient has no contraindications to therapy per drug package insert</li> <li>• The medication is being prescribed at a dose that is within FDA approved/NCCN guidelines.</li> <li>• If the request is for a reference biologic drug with either a biosimilar or interchangeable biologic drug currently available, documentation of one of the following: <ul style="list-style-type: none"> <li>○ The provider has verbally or in writing submitted a member specific reason why the reference biologic is</li> </ul> </li> </ul>

<p>Revision/Review 11/2024</p>	<p>required based on the member's condition or treatment history</p> <ul style="list-style-type: none"><li>○ The currently available biosimilar product does not have the same appropriate use (per the references outlined in "Covered Uses") as the reference biologic product being requested</li></ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgment, the requested item is medically necessary.</b></p>
------------------------------------	---

Field Name	Field Description
Prior Authorization Group Description	<b>Pompe Disease Agents</b>
Drugs	Lumizyme (alglucosidase alfa) Nexviazyme (avalglucosidase alfa-ngpt) injection Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restrictions	According to FDA approved prescribing information
Prescriber Restrictions	Prescribed by, or in consultation with, a specialist in the treatment of Pompe disease, such as a genetic or metabolic specialist, neurologist, cardiologist, or pediatrician.
Coverage Duration	If all of the criteria are met, the request will be approved for 12 months.
Other Criteria	<p><b><u>**Drug is being requested through the member’s medical benefit**</u></b></p> <p><b><u>Initial Authorization:</u></b></p> <p>For infantile onset Pompe Disease (Lumizyme only):</p> <ul style="list-style-type: none"> <li>• Patient has a diagnosis of infantile-onset Pompe Disease, confirmed by one of the following: <ul style="list-style-type: none"> <li>○ Enzyme assay showing a deficiency of acid alpha-glucosidase (GAA) activity in the blood, skin, or muscle</li> <li>○ Genetic testing showing a mutation in the GAA gene</li> </ul> </li> <li>• Requested dose is appropriate per prescribing information (documentation of patient weight must be submitted with request)</li> <li>• Requested regimen will not be used in combination with other enzyme replacement therapies</li> </ul> <p>For late onset Pompe Disease (Lumizyme, Nexviazyme, or Pombiliti + Opfolda):</p> <ul style="list-style-type: none"> <li>• Patient has a diagnosis of late-onset (non-infantile) Pompe Disease, confirmed by one of the following: <ul style="list-style-type: none"> <li>○ Enzyme assay showing a deficiency of acid alpha-glucosidase (GAA) activity in the blood, skin, or muscle</li> <li>○ Genetic testing showing a mutation in the GAA gene</li> </ul> </li> <li>• Documentation patient has measurable signs or symptoms of Pompe disease</li> <li>• Results of a baseline 6-minute walk test (6MWT) and percent-predicted forced vital capacity (FVC) are provided (not required for patients who are not old enough to walk)</li> </ul>

<p>Revision/Review Date: 2/2025</p>	<ul style="list-style-type: none"> <li>• Requested dose is appropriate per prescribing information (documentation of patient weight must be submitted with request)</li> <li>• Requested regimen will not be used in combination with other enzyme replacement therapies (Exception: Pombiliti + Opfolda are to be used together)</li> <li>• Additionally for Nexviazyme: Patients &lt; 30 kg must provide documentation of a trial and therapy failure of, or a medical reason why Lumizyme may not be used.</li> <li>• Additionally for Pombiliti + Opfolda: Patient must have trial and failure of another enzyme therapy (Lumizyme or Nexviazyme)</li> </ul> <p><b><u>Re-Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Documentation or provider attestation of positive clinical response to therapy <ul style="list-style-type: none"> <li>○ Infantile onset: provider attestation of member benefit</li> <li>○ Late onset: improvement, stabilization, or slowing of progression of percent-predicted FVC and/or 6MWT</li> </ul> </li> <li>• Requested dose is appropriate per prescribing information (documentation of patient weight must be submitted with request)</li> <li>• Requested regimen will not be used in combination with other enzyme replacement therapies (Exception: Pombiliti + Opfolda are to be used together)</li> </ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>
---	---

Field Name	Field Description
Prior Authorization Group Description	<b>Primary Hemophagocytic Lymphohistiocytosis (HLH) Agents</b>
Drugs	Gamifant (emapalumab-lzsg)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	Members who have undergone hematopoietic stem cell transplantation (HSCT)
Required Medical Information	“See Other Criteria”
Age Restrictions	N/A
Prescriber Restrictions	Hematologist, Oncologist, Immunologist, Transplant Specialist, or other specialist experienced in the treatment of immunologic disorders
Coverage Duration	Initial Authorization: 1 month Reauthorization: 3 months
Other Criteria	<p><b>*Gamifant will only be approved for members who have not yet received HSCT and will be discontinued at the initiation of HSCT*</b></p> <p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b>Initial Authorization</b></p> <ul style="list-style-type: none"> <li>• Member has a diagnosis of Primary HLH</li> <li>• Prescriber attests that member has not achieved a satisfactory response to or is intolerant to conventional HLH therapy (e.g. etoposide, dexamethasone) or has recurrent disease</li> <li>• Prescriber attests that the member is a candidate for hematopoietic stem cell transplant (HSCT)</li> <li>• Member has been screened for latent tuberculosis infection</li> <li>• Member has or will receive prophylactic pre-medications (e.g. antivirals, antibiotics, antifungals) for Herpes Zoster, <i>Pneumocystis jirovecii</i>, and other fungal infections</li> <li>• Dosing is consistent with FDA approved labeling</li> </ul> <p><b>Reauthorization</b></p> <ul style="list-style-type: none"> <li>• Member continues to meet initial authorization criteria</li> </ul>



Revision/Review Date 4/2024	<ul style="list-style-type: none"><li>• Member is receiving prophylactic pre-medications (e.g. antivirals, antibiotics, antifungals) for Herpes Zoster, <i>Pneumocystis jirovecii</i>, and other fungal infections</li></ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>
--------------------------------	--

Field Name	Field Description
Prior Authorization Group Description	Qalsody (tofersen)
Drugs	Qalsody (tofersen)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	See “Other Criteria”
Required Medical Information	See “Other Criteria”
Age Restrictions	According to package insert
Prescriber Restrictions	Prescribed by or in consultation with a neurologist, neuromuscular specialist, or physician specializing in the treatment of amyotrophic lateral sclerosis (ALS)
Coverage Duration	If all the criteria are met, initial and renewal requests will be approved for 6 months
Other Criteria	<p><b><u>**Drug is being requested through the member’s medical benefit**</u></b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Diagnosis of ALS</li> <li>• Documentation of genetic test confirming a mutation in the superoxide dismutase 1 (SOD1) gene</li> <li>• Member is not dependent on invasive ventilation or tracheostomy</li> <li>• Documentation of slow vital capacity (SVC) <math>\geq 50\%</math></li> <li>• Medication is prescribed at an FDA approved dose</li> </ul> <p><b><u>Re-Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Documentation or provider attestation of positive clinical response (e.g., reduction in the mean concentration of neurofilament light [NfL] chains in the plasma, reduction in concentration of SOD1 in cerebrospinal fluid (CSF), or improvement in the Revised ALS Functional Rating Scale (ALSFRS-R) total score)</li> <li>• Member is not dependent on invasive ventilation or tracheostomy</li> <li>• Medication is prescribed at an FDA approved dose</li> </ul> <p><b>If all of the above criteria are not met, the request is referred to a Medical Director/Clinical Reviewer for medical necessity review.</b></p>
Review/Revision Date: 7/2024	

Field Name	Field Description
Prior Authorization Group Description	<b>Radicava</b>
Drugs	Radicava, Radivaca ORS (edaravone) and any other newly marketed agent
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, the Drug Package Insert, and/or per the standard of care guidelines
Exclusion Criteria	N/A
Required Medical Information	See “other criteria”
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be a neurologist
Coverage Duration	If the criteria are met, requests will be approved for up to 6 month duration
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b>Initial Authorization:</b></p> <ul style="list-style-type: none"> <li>• Member must have a diagnosis of ALS</li> <li>• Member must have a documented baseline evaluation of functionality using the revised ALS functional rating scale (ALSFRS-R) score <math>\geq 2</math></li> <li>• Member’s disease duration is 2 years or less</li> <li>• Member has a baseline forced vital capacity (FVC) of <math>\geq 80\%</math></li> <li>• Member has been on riluzole (Rilutek), is beginning therapy as an adjunct to treatment with Radicava, or provider has provided a medical reason why patient is unable to use riluzole</li> <li>• Dose is within FDA approved limits</li> </ul> <p><b><u>Reauthorization:</u></b></p> <ul style="list-style-type: none"> <li>• Member is not ventilator-dependent</li> <li>• Provider documents clinical stabilization in symptoms (e.g. stabilization of ALSFRS-R score)</li> <li>• Dose is within FDA approved limits</li> </ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>
Revision/Review Date 4/2024	

## **Rituximab**

### **Drugs:**

Rituxan (rituximab)

Rituxan Hycela (rituximab/hyaluronidase human, recombinant)

Truxima (rituximab-abbs)

Ruxience (rituximab-pvvr)

Riabni (rituximab-arrx)

### **RITUXIMAB WILL BE APPROVED IF THE FOLLOWING PRIOR AUTHORIZATION CRITERIA IS MET:**

**\*\*Drug is being requested through the member's medical benefit\*\***

### **MULTIPLE SCLEROSIS:**

#### **Initial Authorization**

- The medication is being prescribed at a dose consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature
- The medication is being prescribed by a neurologist
- Attestation that the patient has been screened for and does not have active hepatitis B virus (HBV)
- For requests for Clinically Isolated Syndrome (CIS), Relapsing Remitting MS (RRMS), Secondary Progressive MS (SPMS): documented trial of at least two preferred agents or a documented medical reason (e.g. contraindication, intolerance, hypersensitivity, etc.) for not utilizing preferred multiple sclerosis disease-modifying agents
  - For patients with “highly active” MS, a prior trial with Gilenya (fingolimod), Lemtrada (alemtuzumab), or Tysabri (natalizumab) will be acceptable.
- For requests for Primary Progressive MS (PPMS) approve if all other criteria have been met
- If the request is for any medication other than Ruxience (rituximab-pvvr), there is a documented trial and failure of Ruxience (rituximab-pvvr), or medical reason why (e.g. intolerance, hypersensitivity, contraindication) it cannot be used
- If the request is for Rituxan Hycela (rituximab/hyaluronidase), all of the above AND documented medical reason why the patient cannot use Rituxan (rituximab).

If all of the above conditions are met, the request will be approved for up to a 1 year duration; if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

### **Reauthorization**

- Documentation that the prescriber has evaluated the member and recommends continuation of therapy (clinical benefit)
- The medication is being prescribed at a dose consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature

If all of the above conditions are met, the request will be approved for up to a 1 year duration; if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

### **NEUORMYELITIS OPTICA SPECTRUM DISORDER (NMOSD):**

#### **Initial Authorization**

- Member has a diagnosis of NMOSD
- Documentation indicating that the patient has been screened for HBV (hepatitis B virus) prior to initiation of treatment
- Dosing is supported by compendia or standard of care guidelines
- If the request is for any medication other than Ruxience (rituximab-pvvr), there is a documented trial and failure of Ruxience (rituximab-pvvr), or medical reason why (e.g. intolerance, hypersensitivity, contraindication) it cannot be used

If all of the above conditions are met, the request will be approved for up to a 1 year duration; if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

#### **Reauthorization**

- Documentation that the prescriber has evaluated the member and recommends continuation of therapy (clinical benefit)
- Request is for an FDA approved/medically accepted dose

If all of the above conditions are met, the request will be approved for up to a 1 year duration; if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

## **RHEUMATOID ARTHRITIS:**

### **Initial Authorization**

- The medication is being recommended and prescribed by a rheumatologist.
- The patient is an adult ( $\geq 18$  y/o) and has a documented clinical diagnosis of rheumatoid arthritis.
- The patient has a documented (consistent with pharmacy claims data, OR for new members to the health plan consistent with medical chart history) adequate trial (including dates and doses) of 3 months or more of therapy with one conventional (non-biologic) DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) or has a documented medical reason (e.g. intolerance, hypersensitivity) for not utilizing any of these therapies to manage their medical condition.
- The patient has a documented (consistent with pharmacy claims data, OR for new members to the health plan consistent with medical chart history) adequate trial (including dates, doses) of 2 preferred biologics indicated for rheumatoid arthritis, or has documented medical reason (intolerance, hypersensitivity, etc.) for not taking the preferred therapies to manage their medical condition.
- Documentation indicating that rituximab is being used concurrently with methotrexate, or a medical reason why methotrexate cannot be used.
- Documentation indicating that the patient has been screened for Hepatitis B Virus (HBV) prior to initiation of treatment.
- Rituximab is being prescribed at an FDA approved dosage.
- If the request is for any medication other than Ruxience (rituximab-pvvr) or Riabni (rituximab-arxx), there is a documented trial and failure of Ruxience or Riabni, or medical reason why (e.g. intolerance, hypersensitivity, contraindication) they cannot be used.

If all of the above conditions are met, the request will be approved for up to a 1 month duration; if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

### **Reauthorization**

- The member has been receiving rituximab and documentation is provided that a rheumatologist has reevaluated the member and recommends continuation of therapy.
- Documentation was provided indicating that the patient had clinical benefit from receiving rituximab therapy.
- At least 16 weeks (4 months) has elapsed since the previous course of rituximab therapy.
- Documentation indicating that rituximab is being used concurrently with methotrexate, or

a medical reason why methotrexate cannot be used.

- Rituximab is being prescribed at an FDA approved dosage.

If all of the above conditions are met, the request will be approved for up to a 1 year duration; if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

## **PEMPHIGUS VULGARIS**

### **Initial Authorization**

- The medication is being recommended and prescribed by a rheumatologist or dermatologist
- The patient is  $\geq 18$  years with a diagnosis of moderate to severe pemphigus vulgaris
- Documentation the patient will be receiving P. jirovecii pneumonia (PJP) prophylaxis (ex. TMP/SMX, dapsone, atovaquone) or the prescriber has provided a medical reason for not prescribing PJP prophylaxis
- Documentation indicating that the patient has been screened for HBV prior to initiation of treatment
- Rituximab is being prescribed at an FDA approved dose/frequency
- Rituximab is being used in combination with a tapering course of glucocorticoids

If all of the above conditions are met, the request will be approved for up to a 1 month duration; if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

### **Reauthorization**

- Documentation of clinical benefits (e.g., absence of new lesions) with rituximab therapy was provided by a rheumatologist or dermatologist
- Documentation the patient will continue to receive PJP prophylaxis (ex. TMP/SMX, dapsone, atovaquone) or the prescriber has provided a medical reason for not prescribing PJP prophylaxis
- Rituximab is being prescribed at an FDA approved dose/frequency

If all of the above conditions are met, the request will be approved for up to a 1 year duration; if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

## **ONCOLOGY INDICATIONS**

### **Initial Authorization:**

- The medication is being recommended and prescribed by an oncologist.
- The medication is being requested for a labeled indication or the an indication supported by a NCCN category 1 or 2A level of evidence
- Documentation of CD20 positive disease
- Documentation indicating that the patient has been screened for HBV prior to initiation of treatment.
- Rituximab is being prescribed at a dose that is within FDA approved guidelines and/or is supported by the medical compendium as defined by the Social Security Act and/or the National Comprehensive Cancer Network (NCCN) or American Society of Clinical Oncology (ASCO) standard of care guidelines.
- If the request is for any medication other than Ruxience (rituximab-pvvr) there is a documented trial and failure of Ruxience (rituximab-pvvr), or medical reason why (e.g. intolerance, hypersensitivity, contraindication) Ruxience (rituximab-pvvr) cannot be used.
- If the request is for Rituxan Hycela (rituximab/hyaluronidase human, recombinant):
  - The patient has received at least one full dose of a rituximab product by intravenous infusion
  - The medication is being requested for a malignant condition
  - There is a medical reason why the alternative rituximab product cannot be continued

If all of the above conditions are met, the request will be approved for up to a 3 month duration;  
if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

### **Reauthorization**

- The medication is being recommended and prescribed by an oncologist.
- Rituximab is being prescribed at a dose that is within FDA approved guidelines and/or is supported by the medical compendium as defined by the Social Security Act and/or per the NCCN or ASCO standard of care guidelines.

If all of the above conditions are met, the request will be approved for up to a 3 month duration;  
if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.



**GRANULOMATOSIS WITH POLYANGIITIS (GPA) (WEGENER'S GRANULOMATOSIS) AND MICROSCOPIC POLYANGIITIS (MPA):**

**Initial Authorization:**

- The medication is being recommended and prescribed by a rheumatologist or nephrologist.
- The patient is 2 years of age or older and has a documented clinical diagnosis of GPA (Wegener's Granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA), or MPA AND the prescriber indicates whether there is severe or non-severe disease.
- Documentation indicating that rituximab is being used concurrently with glucocorticoids.
- Documentation the patient will be receiving PJP prophylaxis (ex. TMP/SMX, dapsone, atovaquone) during treatment or the prescriber has provided a medical reason for not prescribing PJP prophylaxis
- Documentation indicating that the patient has been screened for HBV prior to initiation of treatment.
- Rituximab is being prescribed at an FDA approved dosage.
- If the patient is 18 years of age or older, and the request is for any medication other than Ruxience (rituximab-pvvr) or Riabni (rituximab-arxx), there is a documented trial and failure of Ruxience or Riabni, or medical reason why (e.g. intolerance, hypersensitivity, contraindication) they cannot be used.

If all of the above conditions are met, the request will be approved for up to a 1 month duration; if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

**Re-authorization:**

- The medication is being recommended and prescribed by a rheumatologist or nephrologist.
- Documentation the patient will continue to receive PJP prophylaxis (ex. TMP/SMX, dapsone, atovaquone) or the prescriber has provided a medical reason for not prescribing PJP prophylaxis
- Rituximab is being prescribed at an FDA approved dose.

If all of the above conditions are met, the request will be approved for up to a 1 year duration; if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

## **DERMATOMYOSITIS (DM) and POLYMYOSITIS (PM)**

### **Initial Authorization:**

- Rituximab is being recommended and prescribed by a neurologist, rheumatologist, or dermatologist.
- Patient meets one of the following:
  - Bohan and Peter score indicating definite DM or PM
  - Bohan and Peter score indicating probable DM or PM AND concurring diagnostic evaluation by  $\geq 1$  specialist (e.g. neurologist, rheumatologist, dermatologist)
- Patient does NOT have cancer associated myositis defined as myositis within 2 years of cancer diagnosis (except basal or squamous cell skin cancer or carcinoma in situ of the cervix that has been excised and cured)
- One of the following:
  - Patient has a documented trial and failure of, or has a documented medical reason for not using methotrexate (MTX) OR azathioprine
  - Patient has severe, life-threatening weakness or dysphagia
- Rituximab is prescribed at a dose per the medical compendia (Micromedex, American Hospital Formulary Service (AHFS), DrugPoints, the Drug Package Insert as defined in the Social Security Act and/or per the American Academy of Pediatrics (AAP) standard of care guidelines and has a Class I or IIa recommendation).
- If the request is for any medication other than Ruxience (rituximab-pvvr) there is a documented trial and failure of Ruxience (rituximab-pvvr), or medical reason why (e.g. intolerance, hypersensitivity, contraindication) Ruxience (rituximab-pvvr) cannot be used.

If all of the above conditions are met, the request will be approved for up to a 1 month duration;  
if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

### **Re-authorization:**

- Rituximab is being recommended and prescribed by a neurologist, rheumatologist, or dermatologist.
- Documentation was provided indicating that the patient had clinical benefit from receiving rituximab therapy.
- Rituximab is prescribed at a medically accepted dose per the medical compendia.

If all of the above conditions are met, the request will be approved for up to a 3 month duration;  
if all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

## **OTHER MEDICALLY ACCEPTED INDICATIONS**

### **Initial Authorization:**

- The medication is prescribed for a non-FDA approved indication but is considered to be a medically accepted use of the medication per the medical compendia (Micromedex, American Hospital Formulary Service (AHFS), DrugPoints, the Drug Package Insert as defined in the Social Security Act and/or per the American Academy of Pediatrics (AAP) standard of care guidelines and has a Class I or IIa recommendation.
- The medication is prescribed at a medically accepted dose per the medical compendia as defined above.
- The medication is recommended and prescribed a specialist in the field to treat the member's respective medical condition.
- Documentation indicating that the patient has been screened for HBV prior to initiation of treatment.
- Documentation was submitted indicating that the member has a documented (consistent with pharmacy claims data, OR for new members to the health plan consistent with medical chart history) adequate trial (including dates, doses of medications) of ALL first line medical therapies as recommended by the medical compendia and standard care guidelines and/or has another documented medical reason (e.g. intolerance, contraindications, etc.) for not receiving or trying all first line medical treatment(s).
- If the request is for any medication other than Ruxience (rituximab-pvvr) there is a documented trial and failure of Ruxience (rituximab-pvvr), or medical reason why (e.g. intolerance, hypersensitivity, contraindication) Ruxience (rituximab-pvvr) cannot be used.

If all of the above conditions are met, the request will be approved for up to a 3 month duration.

If all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

### **Re-authorization:**

- The medication is prescribed at a medically accepted dose per the medical compendia
- The medication is recommended and prescribed a specialist in the field to treat the member's respective medical condition.
- Documentation from medical chart was submitted indicating that the member has significantly clinically benefited from the medication.

If all of the above conditions are met, the request will be approved for up to a 3 month duration.

If all of the above criteria are not met, the request is referred to a Medical Director/clinical reviewer for medical necessity review.

**NOTE: Physician/clinical reviewer must override criteria when, in his/her professional judgment, the requested item is medically necessary.**

Revision/Review Date: 7/2024

Field Name	Field Description
Prior Authorization Group Description	<b>Rytelo</b>
Drugs	Rytelo (imetelstat)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restrictions	Member must be 18 years of age and older
Prescriber Restrictions	Prescriber must be a hematologist or oncologist
Coverage Duration	If all of the criteria are met, the initial request will be approved for 6 months. For continuation of therapy, the request will be approved for 6 months.
Other Criteria	<p><b><u>**Drug is being requested through the member’s medical benefit**</u></b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Diagnosis of myelodysplastic syndromes (MDS) with transfusion-dependent anemia</li> <li>• Myelodysplastic Syndrome Revised International Prognostic Scoring System (IPSS-R) categorization as low or intermediate-1 risk of progression</li> <li>• Member has transfusion burden of 4 or more red blood cell (RBC) units within an 8-week period over the last 4 months</li> <li>• Prescriber attestation that complete blood cell count (CBC) will be obtained prior to initiation, weekly for first two cycles, and prior to each cycle thereafter</li> <li>• Member’s weight has been provided with request</li> <li>• Medication is prescribed at an FDA approved dose</li> </ul> <p><b><u>Re-Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Documentation or provider attestation of reduction in RBC transfusion burden as compared with baseline</li> <li>• Provider attestation that patient is tolerating the medication and is not experiencing any serious adverse reactions</li> <li>• Member’s weight has been provided with request</li> <li>• Medication is prescribed at an FDA approved dose</li> </ul>
Revision/ Review Date: 11/2024	

	<b>If all of the above criteria are not met, the request is referred to a Medical Director/Clinical Reviewer for medical necessity review.</b>
--	--

Field Name	Field Description
Prior Authorization Group Description	Somatostatin Analogs and Growth Hormone Receptor Antagonists
Drugs	<p>Octreotide (Sandostatin)  Sandostatin LAR (octreotide)  Lanreotide 120 mg/0.5 mL  Somatuline Depot (lanreotide) 60 mg/0.2 mL, 90 mg/0.3 mL, 120 mg/0.5mL  Mycapssa (octreotide)  Signifor (pasireotide)  Signifor LAR (pasireotide)  Somavert (pegvisomant)</p>
Covered Uses	<p>Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA) Drug Package Insert (PPI).</p> <p><b>** Non-FDA approved (i.e. off-label) uses; refer to the “Oncology Drugs” policy for off-label oncology uses**</b></p>
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restrictions	Per FDA approved package insert
Prescriber Restrictions	Prescriber must be a specialist with appropriate expertise in treating the condition in question (such as an endocrinologist, neurologist/neurosurgeon, oncologist, etc.). Consultation with appropriate specialist for the condition in question is also acceptable.
Coverage Duration	If all of the criteria are met, the initial request will be approved for 6 months. For continuation of therapy, the request will be approved for 12 months.
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b><u>Initial Authorization</u></b></p> <p><u>For all FDA approved indications (including FDA-approved oncology related uses)</u></p> <ul style="list-style-type: none"> <li>• Medication requested is for an FDA approved indication and dose</li> <li>• If the provider is requesting therapy with more than one somatostatin analog or a somatostatin analog and a growth hormone receptor antagonist, then documentation must be submitted as to why patient is unable to be treated with monotherapy, or a medical reason was provided why monotherapy is not appropriate.</li> </ul> <p><u>For Acromegaly</u></p>

<p>Revision/Review Date 4/2024</p>	<ul style="list-style-type: none"> <li>• Patient has had an inadequate response to, or medical reason why, surgical treatment cannot be used.</li> <li>• If the patient mild disease (e.g. mild signs and symptoms of growth hormone excess, modest elevations in IGF-1) there is a documented trial of a dopamine agonist (e.g. bromocriptine mesylate, cabergoline) at a therapeutically appropriate dose or a documented medical reason why a dopamine agonist cannot be used</li> <li>• <b>Additionally for Mycapssa:</b> <ul style="list-style-type: none"> <li>○ Patient has showed clinical response to and tolerates treatment with octreotide or lanreotide therapy</li> <li>○ Clinical justification is provided as to why patient cannot continue use of injectable somatostatin analog therapy</li> </ul> </li> <li>• <b>Additionally for Somavert:</b> <ul style="list-style-type: none"> <li>○ Patient has had an inadequate response to therapy with a somatostatin analog, or has a documented medical reason why a somatostatin analog cannot be used</li> </ul> </li> <li>• <b>Additionally for Signifor LAR:</b> <ul style="list-style-type: none"> <li>○ Patient has had an inadequate response to therapy with either lanreotide (Somatuline Depot) or octreotide (Sandostain, Sandostatin LAR), or has a documented medical reason why these somatostatin analogs cannot be used.</li> </ul> </li> </ul> <p><u>For Cushing's Disease (pasireotide products only)</u></p> <ul style="list-style-type: none"> <li>• Patient must have had inadequate response, or medical reason why surgical treatment cannot be used</li> </ul> <p><b><u>Reauthorization</u></b></p> <ul style="list-style-type: none"> <li>• Medication requested is for an FDA approved indication and dose</li> <li>• Documentation has been provided that demonstrates a clinical benefit (e.g. improvement in laboratory values, improvement or stabilization of clinical signs/symptoms, etc.)</li> </ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>
--	---



Field Name	Field Description
Prior Authorization Group Description	<b>Specialty Drugs</b>
Drugs	Oral and injectable specialty drugs without drug or class specific prior authorization criteria  *** The Oncology Drugs prior authorization criteria will be applied to oncology drugs without drug or class specific criteria***
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restrictions	According to package insert
Prescriber Restrictions	N/A
Coverage Duration	If all of the conditions are met, requests will be approved for up to 6 months. If the conditions are not met, the request will be sent to a Medical Director/clinical reviewer for medical necessity review.
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b>All of the following criteria must be met:</b></p> <ul style="list-style-type: none"> <li>• The drug is requested for an appropriate use (per the references outlined in “Covered Uses”)</li> <li>• The dose requested is appropriate for the requested use (per the references outlined in “Covered Uses”)</li> <li>• Documentation has been provided of a trial and failure of an appropriate alternative first line therapy, if one exists, for the requested use (per the references outlined in “Covered Uses”) or has a medical reason why these drug(s) cannot be used (e.g. intolerance, contraindication)</li> <li>• If the request is for a reference biologic drug with either a biosimilar or interchangeable biologic drug currently available <ul style="list-style-type: none"> <li>○ The provider has either verbally or in writing submitted a member specific reason why the reference biologic is required based on the member’s condition or treatment history</li> <li>○ The currently available biosimilar product does not have the same appropriate use (per the references outlined in “Covered Uses”) as the reference biologic drug being requested</li> </ul> </li> </ul>
Revision/Review Date 4/2024	

	<b>Physician/clinical reviewer must override criteria when, in his/her professional judgment, the requested item is medically necessary.</b>
--	--

Field Name	Field Description
Prior Authorization Group Description	<b>Tecelra</b>
Drugs	Tecelra (afamitresgene autoleucel)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	<ul style="list-style-type: none"> <li>• Homozygous or heterozygous for HLA-A*02:05P</li> </ul>
Required Medical Information	See “Other Criteria”
Age Restrictions	According to package insert
Prescriber Restrictions	Prescriber must be an oncologist
Coverage Duration	If all of the criteria are met, the initial request will be approved for a one-time treatment.
Other Criteria	<p><b><u>**Drug is being requested through the member’s medical benefit**</u></b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Diagnosis of unresectable or metastatic synovial sarcoma</li> <li>• Documentation that patient is HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive</li> <li>• Documentation that the tumor expresses the MAGE-A4 antigen</li> <li>• Documentation of treatment with prior chemotherapy</li> <li>• Member must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1</li> <li>• Medication is being prescribed at an FDA approved dose</li> </ul> <p><b>The safety and effectiveness of repeat administration of Tecelra has not been evaluated and will not be approved.</b></p> <p><b>If all of the above criteria are not met, the request is referred to a Medical Director/Clinical Reviewer for medical necessity review.</b></p>

Date: 11/2024

Field Name	Field Description
Prior Authorization Group Description	<b>Transthyretin-mediated Amyloidosis Agents</b>
Drugs	<p><b><u>Preferred:</u></b>  Polyneuropathy – Onpattro (patisiran), Amvuttra (vutrisiran), Wainua (eplontersen)  Cardiomyopathy – Vyndaqel (tafamidis meglumine), Vyndamax (tafamidis)</p> <p><b><u>Non-preferred:</u></b>  Polyneuropathy – Tegsedi (inoterson)  Or any other newly marketed agent</p>
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restrictions	Patient must be 18 years of age or older
Prescriber Restrictions	Prescriber must be neurologist, cardiologist, or specialist in the treatment of amyloidosis
Coverage Duration	<p>If all of the criteria are met, the initial request will be approved for 6 months.</p> <p>For continuation of therapy the request will be approved for 6 months.</p>
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>Regimen does not exceed FDA-approved dose/frequency</li> <li>Patient has not undergone a liver or heart transplant</li> <li>Patient is not taking any of these agents concurrently: Tegsedi, Onpattro, Amvuttra, Vyndaqel, Vyndamax, or Wainua</li> </ul> <p>If the request is for Onpattro, Amvuttra, Tegsedi, or Wainua:</p> <ul style="list-style-type: none"> <li>Patient has diagnosis of polyneuropathy of hereditary transthyretin-mediated amyloidosis as evidenced by documented transthyretin variant by genotyping</li> <li>One of the following: <ul style="list-style-type: none"> <li>Patient has baseline polyneuropathy disability (PND) score <math>\leq</math> IIIb</li> <li>Patient has a baseline FAP Stage 1 or 2</li> <li>Patient has baseline neuropathy impairment (NIS) score <math>\geq 5</math> and <math>\leq 130</math></li> </ul> </li> </ul>

<p>Revision/Review Date:4/2024</p>	<ul style="list-style-type: none"> <li>• Patient has clinical signs/symptoms of neuropathy</li> <li>• For Tegsedi, patient has contraindication to/or previous trial and failure of use of Onpattro, Amvuttra, or Wainua</li> </ul> <p>If the request is for Vyndaqel or Vyndamax:</p> <ul style="list-style-type: none"> <li>• Patient has a confirmed diagnosis of cardiomyopathy of wild-type or hereditary transthyretin-mediated</li> <li>• Documented amyloid deposit by biopsy or positive technetium 99m pyrophosphate (Tc 99m PYP) cardiac imaging</li> <li>• Patient has New York Heart Association (NYHA) functional class I, II, or III heart failure symptoms.</li> </ul> <p><b><u>Re-authorization (for continuing and new patients to the plan) :</u></b></p> <ul style="list-style-type: none"> <li>• Patient's regimen does not exceed FDA-approved dose/frequency for the agent</li> <li>• Patient has not undergone a liver or heart transplant</li> <li>• Patient is not taking any of these agents concurrently: Tegsedi, Onpattro, Amvuttra, Vyndaqel, Vyndamax, or Wainua)</li> <li>• Documented positive clinical response to therapy from baseline (stabilization/slowing of disease progression, improved neurological impairment, motor functions, improved NIS score, stabilization/reduced rate of decline in 6 minute walk test, etc.)</li> <li>• If the request is for Vyndaqel/Vyndamax <ul style="list-style-type: none"> <li>○ Patient has continued NYHA functional class I, II, or III heart failure symptoms</li> </ul> </li> </ul> <p><b><u>Continuation of Therapy Provision:</u></b></p> <p>Members with history (within the past 90 days) of a non-formulary product are not required to try a formulary agent prior to receiving the non-formulary product.</p> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgment, the requested item is medically necessary.</b></p>
--	--

Field Name	Field Description
Prior Authorization Group Description	<b>Treatments for Plasminogen Deficiency Type 1 (PLD1)</b>
Drugs	Ryplazim (human plasma-derived plasminogen)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), and the Drug Package Insert (PPI).
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be a hematologist, medical geneticist, or other specialist in the treatment of rare blood or genetic disorders
Coverage Duration	If all of the criteria are met, the initial request will be approved for 12 weeks. Reauthorization requests will be approved for 12 weeks if the member has not had a documented positive response to therapy and for 12 months if the member has had a documented positive response to therapy.
Other Criteria	<p><b>**Drug is being requested through the member’s medical benefit**</b></p> <p>Initial Authorization</p> <ul style="list-style-type: none"> <li>• Member must have a diagnosis of PLD1 (i.e. hypoplasminogenemia)</li> <li>• Member must have a documented history of lesions or other symptoms consistent with the diagnosis (e.g. ligneous conjunctivitis, oral, respiratory, gastrointestinal, urogenital, integumentary, or central nervous system manifestations)</li> <li>• Member must have baseline plasminogen activity levels <math>\leq 45\%</math> <ul style="list-style-type: none"> <li>○ If the member received plasminogen supplementation with fresh frozen plasma, prescriber attests that a 7-day washout period was performed before obtaining baseline plasminogen activity levels.</li> </ul> </li> <li>• The request is for an FDA approved dose</li> </ul> <p>Reauthorization</p> <ul style="list-style-type: none"> <li>• ONE of the following is true: <ul style="list-style-type: none"> <li>○ Member has a documented positive response to therapy (e.g. reduction in number or size of lesions, no new or recurring lesions)</li> <li>○ Member has not had a documented positive response to therapy and ONE of the following:</li> </ul> </li> </ul>

<p>Revision/Review Date 4/2024</p>	<ul style="list-style-type: none"> <li>▪ If confirmed plasminogen activity levels are <math>\geq 10\%</math> above baseline, then appropriate dosing frequency adjustments must be made.</li> <li>▪ If confirmed plasminogen activity levels are <math>&lt; 10\%</math> above baseline, then appropriate dosing frequency adjustments must be made AND the prescriber must provide a medical justification as to why therapy should be continued.</li> </ul> <ul style="list-style-type: none"> <li>• The request is for an FDA approved dose</li> </ul> <p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>
--	--

Field Name	Field Description
Prior Authorization Group Description	<b>Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ophthalmic Conditions</b>
Drugs	<p>Preferred Vascular Endothelial Growth Factor (VEGF) Inhibitor(s):</p> <ul style="list-style-type: none"> <li>• <b>Avastin</b> (bevacizumab)</li> <li>• <b>Byooviz</b> (ranibizumab-nuna)</li> <li>• <b>Cimerli</b> (ranibizumab-eqrn)</li> </ul> <p>Non-Preferred Vascular Endothelial Growth Factor (VEGF) Inhibitor(s):</p> <ul style="list-style-type: none"> <li>• <b>Beovu</b> (brolucizumab)</li> <li>• <b>Eylea</b> (aflibercept)</li> <li>• <b>Lucentis</b> (ranibizumab)</li> <li>• <b>Susvimo</b> (ranibizumab)</li> <li>• <b>Vabysmo</b> (faricimab)</li> <li>• <b>Any newly marketed agent in this class</b></li> </ul>
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	See “other criteria”
Age Restrictions	<p>Eylea: approvable in pediatric patients for diagnosis of retinopathy of prematurity</p> <p>All other agents and indications: Approvable for adults 18 years of age and older only</p>
Prescriber Restrictions	Ophthalmologist
Coverage Duration	<p>If the above conditions are met, the request will be approved with a 3 month duration for initial and 12 months for renewal.</p> <p>Retinopathy of Prematurity: approvable for a 6 month duration for initial and renewal requests.</p>



<p>Other Criteria</p>	<p><b>**Drug is being requested through the member's medical benefit**</b></p> <p><b>Avastin:</b></p> <ul style="list-style-type: none"> <li>• Request is for compendia supported dosing for an ophthalmic indication</li> </ul> <p><b>Byooviz or Cimerli:</b></p> <ul style="list-style-type: none"> <li>• Request is for an FDA-approved dosing regimen</li> </ul> <p><b>Non-Preferred VEGF Inhibitor:</b></p> <ul style="list-style-type: none"> <li>• Request is for an FDA-approved dosing regimen; <b>AND</b></li> <li>• Documented trial and failure with a preferred VEGF inhibitor for all FDA-approved indications OR: a medical justification for not using a preferred VEGF inhibitor (e.g. experienced a severe ADR such as hypersensitivity, arterial thromboembolism, cerebrovascular accident, raised intraocular pressure, retinal detachment).</li> <li>• Requests for Eylea (aflibercept) may be approved for a diagnosis of retinopathy of prematurity without a trial and failure of a preferred VEGF inhibitor. Patients must have a diagnosis of retinopathy of prematurity in at least one eye with one of the following retinal findings: <ul style="list-style-type: none"> <li>○ ROP Zone 1 Stage 1+, 2+, 3 or 3+, or</li> <li>○ ROP Zone II Stage 2+ or 3+, or</li> <li>○ AP-ROP (aggressive posterior ROP)</li> </ul> </li> </ul>
<p>Revision/Review Date 11/2024</p>	<p><b>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</b></p>

Field Name	Field Description
Prior Authorization Group Description	<b>Veopoz</b>
Drugs	Veopoz (pozelimab-bbfg)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	<ul style="list-style-type: none"> <li>• Patients with unresolved Neisseria meningitidis infection</li> <li>• Concurrent use of another complement inhibitor (i.e. Soliris)</li> </ul>
Required Medical Information	See "Other Criteria"
Age Restrictions	According to package insert
Prescriber Restrictions	Prescribed by or in consultation with a physician with experience in managing complement related disorders (i.e., gastroenterologist, immunologist, cardiologist, etc.)
Coverage Duration	If all of the criteria are met, the initial request will be approved for 6 months. For continuation of therapy, the request will be approved for 12 months.
Other Criteria	<p><b>**Drug is being requested through the member's medical benefit**</b></p> <p><b><u>Initial Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Medication is prescribed at an FDA approved dose</li> <li>• Diagnosis of CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease</li> <li>• Documentation of hypoalbuminemia (serum albumin &lt;3.5 g/dL)</li> <li>• Documentation of patient weight</li> </ul> <p><b><u>Re-Authorization:</u></b></p> <ul style="list-style-type: none"> <li>• Documentation or provider attestation of positive clinical response (i.e. symptom improvement, normalization of labs such as serum albumin (3.5-5.5 g/dL) and IgG concentrations, reduced hospitalizations and severe adverse events, increased quality of life, etc.)</li> <li>• Documentation of patient weight</li> <li>• Medication is prescribed at an FDA approved dose</li> </ul> <p><b>If all of the above criteria are not met, the request is referred to a Medical Director/Clinical Reviewer for medical necessity review.</b></p>
Revision/Review Date: 11/2024	